 SNG001 is a recombinant interferon beta-1A formulation administered via nebulizer to patients hospitalized with COVID-19. In this clinical trial, SNG001 did not show any statistically significant difference compared to placebo in terms of recovery from hospitalization and progression to severe disease or death. However, it did appear to reduce the risk of progression to intubation or death by 25.7%. This article was offered by Philip D. Monk, Jody L. Brooks, Victoria J. Tehr, and others.